Epilepsy. Epilepsy and recurrent seizures
Conditions
Interventions
Intervention 1: Intervention group: 5 mg Memantine oral tablet once a day for 8 weeks and then 10 mg once a day for another 8 weeks with caution. Intervention 2: Control group: placebo once a day for
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients between 15-65 years old Epileptic patients who received anti epileptic drugs over 6 months with mild to moderate cognition impairment Seizure episodes less than four times a month
Exclusion criteria
Exclusion criteria: Progressive neurologic disease, psychiatric disorders, and mental retardation Severe medical illnesses such as renal failure Pregnancy or breast feeding Patients during inter-ictal phase (2 weeks) Patients with seizure episodes more than four times a month adverse drug effect drug allergy or intolerance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive status score according to MMSE (Folstein mini-mental state examination) criteria. Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Asking questions of MMSE (Folstein mini-mental state examination ).;Cognitive status score according to FAB (Frontal Assessment Battery). Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Asking questions of FAB (Frontal Assessment Battery).;Cognitive status score according to MoCA (Montreal Cognitive Assessment). Timepoint: Before intervention and 16 weeks after intervention. Method of measurement: Asking questions of MoCA (Montreal Cognitive Assessment).;Adverse events. Timepoint: 16 weeks after intervention. Method of measurement: Adverse events form. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbbas Tafakhori
Tehran University of Medical Sciences
Outcome results
None listed